

Sub D1
47. A method for inhibiting Hepatitis B virus (HBV) replication comprising administering a compound that inhibits enhanced activity of Src kinase wherein said enhanced activity results from the presence of HBx.

Sub E
48. A method for inhibiting Hepatitis B virus (HBV) replication in a cell wherein Src kinase activity is enhanced comprising administering a compound that reduces the enhanced activation of Src kinase activity to levels comparable to those observed in the absence of HBV.

C1
49. The method of Claim 47 or 48 wherein the compound that inhibits said enhanced activity of Src kinase is determined by an *in vitro* assay comprising:
a) contacting a cell expressing HBx with the compound;
b) determining whether levels of Src kinase activity are reduced in those cells contacted with the compound as compared to levels of Src kinase activity in cells expressing HBx in the absence of the compound.

50. The method of claim 47 or 48 wherein said compound inhibits a Src kinase signaling cascade component other than Src kinase as determined by an *in vitro* assay comprising:
a) contacting a Src kinase with said compound; and
b) determining whether levels of Src kinase activity in the presence of said compound are substantially equal to levels of Src kinase activity in the absence of said compound.